182 related articles for article (PubMed ID: 31755361)
1. Revealing binding selectivity of ligands toward murine double minute 2 and murine double minute X based on molecular dynamics simulations and binding free energy calculations.
Shi S; Sui K; Liu W; Lei Y; Zhang S; Zhang Q
J Biomol Struct Dyn; 2020 Oct; 38(17):5081-5094. PubMed ID: 31755361
[TBL] [Abstract][Full Text] [Related]
2. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation.
Chen J; Wang J; Zhang Q; Chen K; Zhu W
Sci Rep; 2015 Nov; 5():17421. PubMed ID: 26616018
[TBL] [Abstract][Full Text] [Related]
3. Calculation of hot spots for protein-protein interaction in p53/PMI-MDM2/MDMX complexes.
Huang D; Qi Y; Song J; Zhang JZH
J Comput Chem; 2019 Apr; 40(9):1045-1056. PubMed ID: 30549062
[TBL] [Abstract][Full Text] [Related]
4. Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors.
Zhao X; Xiong D; Luo S; Duan L
Phys Chem Chem Phys; 2022 Jul; 24(27):16799-16815. PubMed ID: 35775962
[TBL] [Abstract][Full Text] [Related]
5. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
Chen J; Zhang D; Zhang Y; Li G
Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
[TBL] [Abstract][Full Text] [Related]
6. Structure-based discovery of novel α-aminoketone derivatives as dual p53-MDM2/MDMX inhibitors for the treatment of cancer.
Luo HJ; Si DJ; Sun XJ; Wang MY; Yang YB; Wang B; Wen HM; Li W; Liu J
Eur J Med Chem; 2023 Apr; 252():115282. PubMed ID: 36989812
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
Lu SY; Jiang YJ; Zou JW; Wu TX
J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
[TBL] [Abstract][Full Text] [Related]
8. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
[TBL] [Abstract][Full Text] [Related]
9. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
10. Computational modeling of cyclic peptide inhibitor-MDM2/MDMX binding through global docking and Gaussian accelerated molecular dynamics simulations.
Wang YT; Cheng TL
J Biomol Struct Dyn; 2021 Jul; 39(11):4005-4014. PubMed ID: 32448094
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
Niu RJ; Zheng QC; Zhang JL; Zhang HX
J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
[TBL] [Abstract][Full Text] [Related]
12. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
Barakat K; Mane J; Friesen D; Tuszynski J
J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
[TBL] [Abstract][Full Text] [Related]
13. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
14. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
15. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
Cai X; Yuan ZM
J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
[TBL] [Abstract][Full Text] [Related]
16. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
17. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.
Zhou T; Ke Z; Ma Q; Xiang J; Gao M; Huang Y; Cheng X; Su Z
Sci Rep; 2023 Dec; 13(1):21892. PubMed ID: 38081879
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex: IMPLICATION OF A NOVEL MDMX SER-314 PHOSPHOSITE.
Gerarduzzi C; de Polo A; Liu XS; El Kharbili M; Little JB; Yuan ZM
J Biol Chem; 2016 Dec; 291(50):25937-25949. PubMed ID: 27777309
[TBL] [Abstract][Full Text] [Related]
20. Application of binding free energy calculations to prediction of binding modes and affinities of MDM2 and MDMX inhibitors.
Lee HS; Jo S; Lim HS; Im W
J Chem Inf Model; 2012 Jul; 52(7):1821-32. PubMed ID: 22731511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
